SCHEMBL16617730

SCHEMBL16617730

COC(=O)[C@H]1CC2CC2C[C@H]1C(=O)OCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPB1 P15086 1/20 0.57
ALDH1A1 P00352 5/20 0.56
TSHR P16473 4/20 0.56
CYP2C9 P11712 3/20 0.56
CYP2C19 P33261 3/20 0.56
CYP1A2 P05177 3/20 0.56
CYP3A4 P08684 3/20 0.56
CYP2D6 P10635 2/20 0.56
POLB P06746 1/20 0.56
LMNA P02545 1/20 0.52
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
F2 P00734 2/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
FKBP1A P62942 1/20 0.47
FABP7 O15540 1/20 0.46
FABP5 Q01469 1/20 0.46
MAPK1 P28482 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16617732 1.00 CPB1 (0.57) CPB1ALDH1A1TSHRCYP2C9CYP2C19
SCHEMBL17947657 0.92 CPB1 (0.61) CPB1ALDH1A1TSHRCYP2C9CYP2C19
SCHEMBL14790608 0.88 CPB1 (0.57) CPB1ALDH1A1TSHRCYP2C9CYP2C19
SCHEMBL14457468 0.88 CPB1 (0.57) CPB1ALDH1A1TSHRCYP2C9CYP2C19
SCHEMBL11930628 0.88 CPB1 (0.57) CPB1ALDH1A1TSHRCYP2C9CYP2C19
SCHEMBL14457509 0.88 CPB1 (0.57) CPB1ALDH1A1TSHRCYP2C9CYP2C19
SCHEMBL11930631 0.88 CPB1 (0.57) CPB1ALDH1A1TSHRCYP2C9CYP2C19
SCHEMBL20344515 0.88 CPB1 (0.57) CPB1ALDH1A1TSHRCYP2C9CYP2C19
SCHEMBL14457473 0.87 CPB1 (0.56) CPB1ALDH1A1TSHRCYP2C9CYP2C19
SCHEMBL18595789 0.85 CPB1 (0.55) CPB1ALDH1A1TSHRCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054947-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-17 EP disclosed
EP-3104705-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-03 EP disclosed
EP-3055314-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2018-09-12 EP disclosed
US-9656990-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-05-23 US disclosed
US-9573913-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-02-21 US disclosed
US-20160355502-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-12-08 US disclosed
US-9458181-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2016-10-04 US disclosed
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-25 US disclosed
EP-3054947-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015054038-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed
US-20150099719-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160355502-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ CPB1 18/4885ALDH1A1 4582/4885TSHR 3675/4885
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ CPB1 18/4885ALDH1A1 4582/4885TSHR 3675/4885
US-20150099719-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ CPB1 18/4885ALDH1A1 4582/4885TSHR 3675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.